1.
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600 -mutated melanoma: a phase 1b study
by Ribas, Antoni, Prof
The lancet oncology, 2014, Vol.15 (9), p.954-965

2.
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
by Larkin, James, Dr
The lancet oncology, 2014, Vol.15 (4), p.436-444

3.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging tri...
by Calais, Jeremie, MD
The lancet oncology, 2019, Vol.20 (9), p.1286-1294

4.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18):...
by Borchmann, Peter, Prof
The lancet oncology, 2017, Vol.18 (4), p.454-463

5.
Dabrafenib plus trametinib in patients with BRAFV600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
by Davies, Michael A, Dr
The lancet oncology, 2017, Vol.18 (7), p.863-873

6.
Dabrafenib plus trametinib in patients with previously treated BRAFV600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
by Planchard, David, MD
The lancet oncology, 2016, Vol.17 (7), p.984-993

7.
Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
by Planchard, David, MD
The lancet oncology, 2016, Vol.17 (5), p.642-650

8.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
by Robert, Caroline, Prof
The lancet oncology, 2019, Vol.20 (9), p.1239-1251

9.
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
by McArthur, Grant A, Prof
The lancet oncology, 2014, Vol.15 (3), p.323-332

12.
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
by Farge, Dominique, MD
The lancet oncology, 2019, Vol.20 (10), p.e566-e581

13.
Reduced carginogens found in e-cigarette users
by Burki, Talha Khan
The lancet oncology, 2017, Vol.18 (3), p.e142-e142

14.
Correction to Lancet Oncol 2016; 17: 234–42
by Anon
The lancet oncology, 2017, Vol.18 (3), p.e134-e134

16.
Cobimetinib combined with vemurafenib in advanced BRAFV600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
by Ascierto, Paolo A, MD
The lancet oncology, 2016, Vol.17 (9), p.1248-1260

17.
A review of human carcinogens—Part F: Chemical agents and related occupations
by Baan, Robert
The lancet oncology, 2009, Vol.10 (12), p.1143-1144

18.
Nomograms in oncology: more than meets the eye
by Balachandran, Vinod P, Dr
The lancet oncology, 2015, Vol.16 (4), p.e173-e180

19.
Correction to Lancet Oncol 2016; 17: 1482
by Anon
The lancet oncology, 2016, Vol.17 (12), p.e519-e519

20.
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study
by De Angelis, Roberta, MSc
The lancet oncology, 2014, Vol.15 (1), p.23-34
